High-Density Info

New developments in protein array technology

Written byKelly Rae Chi
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

BUILT ON THE SPOT: Purified template DNA is printed onto a slide along with bovine serum albumin and an antibody that recognizes glutathione-S-transferase (GST). The DNA template contains both the gene for the protein of interest and for GST (left). LaBaer isn’t sure why bovine serum albumin helps, but it seems to hold the DNA to the surface without inhibiting transcription and may provide some degree of background suppression. Transcription and translation is initiated by the addition of a cell extract, and the protein self-assembles (middle). The GST-tagged protein is then captured by an anti-GST antibody (right).ADAPTED FROM WIKIPEDIA/SIMIN LIM

Thirty years after it came into use, the protein microarray—a high-throughput tool that tracks the presence, activity, and interactions of proteins—is still going strong, even as its DNA counterpart is being replaced by next-generation sequencing. Protein arrays are workhorses in biomarker discovery, immune-response monitoring, and other areas of biology.

Traditional protein microarrays—slides, beads in a liquid, or plates that are specked with hundreds or thousands of proteins, probed and analyzed, often with fluorescent labels—allow an unbiased look at protein function. Unlike other proteomics techniques, arrays immobilize even low-abundance proteins. “The nice thing about protein arrays is that every protein gets its chance. Every protein is there at reasonable levels,” says Josh LaBaer, director of the Virginia G. Piper Center for Personalized Diagnostics at Arizona State ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies